PRESS RELEASE published on 10/16/2025 at 17:51, 11 months 7 days ago Inside Information / News release on accounts, results Poxel reports financial results for full year 2024, including positive net royalties and governance changes. Updates on operational and financial status provided. Commercial momentum for TWYMEEG® in Japan. Cash position and financing details shared Financial Results Cash Position Governance Changes TWYMEEG® Poxel
BRIEF published on 08/08/2025 at 17:50, 1 year 1 month ago POXEL Begins Judicial Reorganization Proceedings Metabolic Diseases Euronext Listing Judicial Recovery Steatohepatitis Observation Period
BRIEF published on 07/29/2025 at 20:21, 1 year 1 month ago Poxel Initiates Reorganization Amid Financial Struggles Creditors Reorganization Insolvency Corporate Changes Poxel
PRESS RELEASE published on 07/29/2025 at 20:16, 1 year 1 month ago Inside Information / Other news releases Poxel provides update on negotiations with creditors, announces reorganization proceedings & corporate governance change with trading suspension. Press release details Lyon Court filing for insolvency & governance impact Governance Creditors Reorganization Trading Suspension Poxel
BRIEF published on 07/08/2025 at 18:51, 1 year 2 months ago Information on Poxel's capital and voting rights Share Capital Voting Rights Actions AMF Poxel
BRIEF published on 06/19/2025 at 17:51, 1 year 3 months ago Key Scientific Presentations on Imeglimin at ADA 2025 Diabetes Therapeutic Potential Sumitomo Pharma Imeglimin Scientific Presentations
PRESS RELEASE published on 06/19/2025 at 17:46, 1 year 3 months ago Inside Information / Other news releases Poxel presents new Imeglimin data at ADA 2025 diabetes conference, highlighting therapeutic potential. Key presentations by Japanese experts Diabetes Therapeutic Potential Poxel Imeglimin ADA 2025
BRIEF published on 06/06/2025 at 19:10, 1 year 3 months ago Poxel: Details of share capital and voting rights Share Capital Voting Rights Actions Regulated Information Poxel
BRIEF published on 05/28/2025 at 07:35, 1 year 3 months ago TWYMEEG® Data Unveiled at Japan Diabetes Society Meeting Clinical Trials Diabetes Treatment TWYMEEG® Poxel SA Japan Diabetes Society
PRESS RELEASE published on 05/28/2025 at 07:30, 1 year 3 months ago Inside Information / Other news releases New clinical and scientific data on TWYMEEG® to be presented at the 68th Annual Meeting of the Japan Diabetes Society, showcasing efficacy, safety, and benefits in diverse patient groups Clinical Data Scientific Data TWYMEEG® Sumitomo Pharma Japan Diabetes Society
Published on 09/23/2026 at 22:00, 4 hours 2 minutes ago Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 7 hours 37 minutes ago Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 10 hours 20 minutes ago Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 11 hours 31 minutes ago First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 11 hours 32 minutes ago Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/23/2026 at 23:00, 3 hours 2 minutes ago Correction of a release from 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNOUNCES THE SUCCESS OF ITS CAPITAL INCREASE WITH PREFERENTIAL SUBSCRIPTION RIGHTS AND THE PARTIAL EARLY REDEMPTION OF BONDS REDEEMABLE IN SHARES
Published on 09/23/2026 at 19:51, 6 hours 11 minutes ago LIGHTON: LightOn renews its bond financing with the same financial partners for a maximum nominal amount of €4 million, and thus extends its cash flow horizon
Published on 09/23/2026 at 18:05, 7 hours 57 minutes ago XPRIZE Wildfire Awards $4.55M to Innovators Advancing Wildfire Detection and Response
Published on 09/23/2026 at 18:00, 8 hours 2 minutes ago ARVERNE GROUP: Release of the 2026 half-year financial report
Published on 09/23/2026 at 18:00, 8 hours 2 minutes ago ARVERNE GROUP: First half of 2026 60.1% growth in gross business volume to €16.8 million Operational performance above expectations
Published on 09/23/2026 at 19:14, 6 hours 48 minutes ago Robust performance from Investments and continued execution of the strategy
Published on 09/23/2026 at 17:45, 8 hours 17 minutes ago Report on share repurchases from 16 to 21 September 2026
Published on 09/23/2026 at 17:45, 8 hours 17 minutes ago Infotel : H1 2026 RESULTS. Revenue growth of +9.4%.
